Search results
Showing 6841 to 6855 of 8213 results
This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.
Lutonix drug-coated balloon for peripheral arterial disease (MIB72)
NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.
We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]
Discontinued Reference number: GID-TA10074
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued Reference number: GID-TA10087
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
Discontinued Reference number: GID-TA10099
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued Reference number: GID-TA10105
Discontinued Reference number: GID-TA10109
Discontinued Reference number: GID-TA10110
Discontinued Reference number: GID-TA10126